Fresenius Kabi AG
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Fresenius Kabi AG
Fresenius Pushes Kabi Even Higher As Former Sandoz Exec Named CEO
The Fresenius group spoke at length about its core Fresenius Kabi business during the company’s year-end financial call, not least its under pressure IV drugs in the US.
‘First Of Many’ For Kabi As It Rolls Out Its First Biosimilar – Pegfilgrastim
Fresenius Kabi has delivered on long held ambitions to join the biosimilars party in the US, offering another pegfilgrastim subcutaneous injectable in a crowded market of biosimilar sponsors.
The Quality Lowdown: The Effort Required To Stem Substandard, Illegitimate, Unapproved Drugs
As stakeholders in the US pharmaceutical distribution chain prepare to coordinate against suspect drugs, the world’s leading inspectorates collaborate on good distribution practices.
Deals, Divestitures In Store As Dr Reddy’s Stays Course To Top Five India League
Investments in differentiated and specialty products and collaborations, alongside divestitures, are part of Dr Reddy’s plans as it seeks to move up the rankings in India. Momentum in China, including an alliance with Sunflower Pharma for orphan diseases, is also being keenly watched.
- Generic Drugs
- Infusion Therapy Equipment and Supplies
- Other Names / Subsidiaries
- mAbxience S.L.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.